Skip to main content

Featured

5 Things to Know Today: Hot U.S. Inflation, BoC Hike Odds, Loonie Slump (Oct. 15)

  Canadian Money Brief | Thursday, October 15, 2026 A hotter-than-expected U.S. inflation print rattled markets Wednesday, just as Canadians wait on their own CPI and a Bank of Canada decision. Here are the five things that matter to your wallet today. 1. Hot U.S. inflation knocks the TSX down 1.1% U.S. consumer prices rose 3.7% in September from a year earlier (up from 3.4% in August), with a 0.6% monthly jump, the biggest in five months; core inflation rose to 2.6% from 2.4%, per the Labor Department. Gasoline jumped 9.1% in the month. CME FedWatch odds of a Fed hike at the Oct. 27-28 meeting roughly doubled but sit near 50-50. The S&P/TSX Composite fell 399.52 points (-1.11%) to 35,584.46 Wednesday, ending a three-day win streak; basic materials sank 4.33%, and all six big banks finished lower. The Nasdaq lost 1.88%. What it means for you: Higher U.S. rates tend to pull Canadian bond yields up too, and that is what fixed mortgage rates follow. If you have a renewal coming,...
Post a Comment
Read more

article

Labels

A New Dawn in Alzheimer’s Prevention: The AHEAD 3-45 Study


The AHEAD 3-45 study represents a beacon of hope for individuals like Tyson Haller, who, at 60, is determined to understand and possibly prevent the onset of Alzheimer’s—a disease that claimed his father. This groundbreaking clinical trial is testing lecanemab, an FDA-approved drug that has shown promise in slowing Alzheimer’s progression in its early stages. The optimism surrounding this trial is palpable, as it could herald a new era where Alzheimer’s is as manageable as Type 2 diabetes.

  • Family History’s Weight: Haller’s participation is driven by his family’s battle with Alzheimer’s, highlighting the emotional and proactive steps taken by those at risk.
  • Lecanemab’s Potential: The trial’s focus on lecanemab, a drug targeting beta amyloid plaques in the brain, offers a glimpse into a future where early intervention could significantly slow the disease’s impact.
  • Scientific Debate: Despite the excitement, there’s a scientific debate about beta amyloid’s role in Alzheimer’s, underscoring the complexity of finding a definitive treatment.
  • Awaiting Results: With the AHEAD and TRAILBLAZER prevention trials running until 2027 and 2029, patients, doctors, and researchers are in a state of limbo, hopeful yet uncertain of the long-term outcomes.

This study not only represents a potential turning point in Alzheimer’s research but also embodies the personal stories of those fighting to preserve their memories and identities against this relentless disease.

Labels:

Comments

Post a Comment